PH12015502019A1 - Sequestrants of advanced glycation end product (age) precursors - Google Patents
Sequestrants of advanced glycation end product (age) precursorsInfo
- Publication number
- PH12015502019A1 PH12015502019A1 PH12015502019A PH12015502019A PH12015502019A1 PH 12015502019 A1 PH12015502019 A1 PH 12015502019A1 PH 12015502019 A PH12015502019 A PH 12015502019A PH 12015502019 A PH12015502019 A PH 12015502019A PH 12015502019 A1 PH12015502019 A1 PH 12015502019A1
- Authority
- PH
- Philippines
- Prior art keywords
- sequestrants
- age
- precursors
- end product
- advanced glycation
- Prior art date
Links
- 239000002243 precursor Substances 0.000 title abstract 5
- 239000003352 sequestering agent Substances 0.000 title abstract 4
- 108010005094 Advanced Glycation End Products Proteins 0.000 title 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000002177 Cataract Diseases 0.000 abstract 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 150000001412 amines Chemical class 0.000 abstract 1
- 208000020832 chronic kidney disease Diseases 0.000 abstract 1
- 208000033679 diabetic kidney disease Diseases 0.000 abstract 1
- 125000004989 dicarbonyl group Chemical group 0.000 abstract 1
- 235000005911 diet Nutrition 0.000 abstract 1
- 230000000378 dietary effect Effects 0.000 abstract 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
- 239000008177 pharmaceutical agent Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F126/00—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen
- C08F126/02—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen by a single or double bond to nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/04—Chelating agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Polymers & Plastics (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Toxicology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Steroid Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361792719P | 2013-03-15 | 2013-03-15 | |
| PCT/US2014/024436 WO2014150873A1 (en) | 2013-03-15 | 2014-03-12 | Sequestrants of advanced glycation end product (age) precursors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12015502019A1 true PH12015502019A1 (en) | 2016-01-11 |
Family
ID=50439508
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH12015502019A PH12015502019A1 (en) | 2013-03-15 | 2015-09-09 | Sequestrants of advanced glycation end product (age) precursors |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US20160024233A1 (enExample) |
| EP (1) | EP2968403A1 (enExample) |
| JP (4) | JP2016512830A (enExample) |
| KR (1) | KR20150130492A (enExample) |
| CN (1) | CN105188718A (enExample) |
| AR (1) | AR095593A1 (enExample) |
| AU (2) | AU2014235500A1 (enExample) |
| BR (1) | BR112015023404A8 (enExample) |
| CA (1) | CA2906501A1 (enExample) |
| CL (1) | CL2015002624A1 (enExample) |
| CR (1) | CR20150545A (enExample) |
| DO (1) | DOP2015000221A (enExample) |
| EA (1) | EA201591733A1 (enExample) |
| HK (1) | HK1220607A1 (enExample) |
| IL (1) | IL241406A0 (enExample) |
| MA (1) | MA38487A1 (enExample) |
| MX (1) | MX2015012843A (enExample) |
| PE (1) | PE20151766A1 (enExample) |
| PH (1) | PH12015502019A1 (enExample) |
| SG (2) | SG10201707590XA (enExample) |
| TN (1) | TN2015000390A1 (enExample) |
| TW (1) | TW201521744A (enExample) |
| UY (1) | UY35441A (enExample) |
| WO (1) | WO2014150873A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA41202A (fr) * | 2014-12-18 | 2017-10-24 | Genzyme Corp | Copolymères polydiallymine réticulé pour le traitement du diabète de type 2 |
| EP3675737A4 (en) * | 2017-08-31 | 2021-02-17 | Cytosorbents Corporation | REDUCTION OF ADVANCED GLYCATION END PRODUCTS FROM BODY FLUIDS |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5985938A (en) * | 1997-11-05 | 1999-11-16 | Geltex Pharmaceuticals, Inc. | Method for reducing oxalate |
| AU2002257145B2 (en) * | 2001-04-18 | 2005-06-02 | Genzyme Corporation | Method for lowering serum glucose |
| WO2005032563A1 (en) * | 2003-09-02 | 2005-04-14 | Genzyme Corporation | Method for reducing vascular inflammation |
| US7385012B2 (en) * | 2003-11-03 | 2008-06-10 | Ilypsa, Inc. | Polyamine polymers |
| US7459502B2 (en) * | 2003-11-03 | 2008-12-02 | Ilypsa, Inc. | Pharmaceutical compositions comprising crosslinked polyamine polymers |
| AU2005214971A1 (en) * | 2004-02-17 | 2005-09-01 | Dynamis Therapeutics, Inc. | Fructoseamine 3 kinase and the formation of collagen and elastin |
| FR2883873B1 (fr) * | 2005-03-31 | 2009-07-10 | Pharmamens Sarl | Inhibiteurs d'age |
| CN105017481B (zh) * | 2010-02-24 | 2018-10-02 | 瑞立普萨公司 | 用作胆汁酸螯合剂的交联聚乙烯胺、聚烯丙胺和乙烯亚胺 |
-
2014
- 2014-03-12 HK HK16108617.8A patent/HK1220607A1/zh unknown
- 2014-03-12 EP EP14715503.0A patent/EP2968403A1/en not_active Withdrawn
- 2014-03-12 CN CN201480026330.6A patent/CN105188718A/zh active Pending
- 2014-03-12 AU AU2014235500A patent/AU2014235500A1/en not_active Abandoned
- 2014-03-12 SG SG10201707590XA patent/SG10201707590XA/en unknown
- 2014-03-12 US US14/776,059 patent/US20160024233A1/en not_active Abandoned
- 2014-03-12 PE PE2015001994A patent/PE20151766A1/es unknown
- 2014-03-12 EA EA201591733A patent/EA201591733A1/ru unknown
- 2014-03-12 BR BR112015023404A patent/BR112015023404A8/pt not_active Application Discontinuation
- 2014-03-12 MA MA38487A patent/MA38487A1/fr unknown
- 2014-03-12 SG SG11201506413PA patent/SG11201506413PA/en unknown
- 2014-03-12 CA CA2906501A patent/CA2906501A1/en not_active Abandoned
- 2014-03-12 MX MX2015012843A patent/MX2015012843A/es unknown
- 2014-03-12 JP JP2016501535A patent/JP2016512830A/ja active Pending
- 2014-03-12 WO PCT/US2014/024436 patent/WO2014150873A1/en not_active Ceased
- 2014-03-12 KR KR1020157028860A patent/KR20150130492A/ko not_active Withdrawn
- 2014-03-13 TW TW103108910A patent/TW201521744A/zh unknown
- 2014-03-14 UY UY0001035441A patent/UY35441A/es not_active Application Discontinuation
- 2014-03-17 AR ARP140101218A patent/AR095593A1/es unknown
-
2015
- 2015-09-04 TN TN2015000390A patent/TN2015000390A1/en unknown
- 2015-09-08 DO DO2015000221A patent/DOP2015000221A/es unknown
- 2015-09-09 IL IL241406A patent/IL241406A0/en unknown
- 2015-09-09 PH PH12015502019A patent/PH12015502019A1/en unknown
- 2015-09-11 CL CL2015002624A patent/CL2015002624A1/es unknown
- 2015-10-13 CR CR20150545A patent/CR20150545A/es unknown
-
2017
- 2017-12-14 US US15/842,177 patent/US20180265613A1/en not_active Abandoned
-
2018
- 2018-04-25 JP JP2018083623A patent/JP2018135365A/ja active Pending
-
2019
- 2019-02-22 AU AU2019201259A patent/AU2019201259A1/en not_active Abandoned
- 2019-12-06 JP JP2019220818A patent/JP2020055850A/ja active Pending
-
2021
- 2021-12-17 JP JP2021204770A patent/JP2022037143A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2018135365A (ja) | 2018-08-30 |
| IL241406A0 (en) | 2015-11-30 |
| AU2019201259A1 (en) | 2019-03-14 |
| BR112015023404A2 (pt) | 2017-07-18 |
| DOP2015000221A (es) | 2015-12-15 |
| TN2015000390A1 (en) | 2017-01-03 |
| TW201521744A (zh) | 2015-06-16 |
| US20180265613A1 (en) | 2018-09-20 |
| CA2906501A1 (en) | 2014-09-25 |
| EP2968403A1 (en) | 2016-01-20 |
| WO2014150873A1 (en) | 2014-09-25 |
| CL2015002624A1 (es) | 2016-03-11 |
| MA38487A1 (fr) | 2017-12-29 |
| EA201591733A1 (ru) | 2016-01-29 |
| AU2014235500A1 (en) | 2015-11-05 |
| CN105188718A (zh) | 2015-12-23 |
| BR112015023404A8 (pt) | 2019-12-03 |
| UY35441A (es) | 2014-10-31 |
| JP2016512830A (ja) | 2016-05-09 |
| JP2020055850A (ja) | 2020-04-09 |
| CR20150545A (es) | 2015-12-01 |
| AR095593A1 (es) | 2015-10-28 |
| PE20151766A1 (es) | 2015-12-11 |
| SG11201506413PA (en) | 2015-09-29 |
| KR20150130492A (ko) | 2015-11-23 |
| SG10201707590XA (en) | 2017-11-29 |
| MX2015012843A (es) | 2016-08-08 |
| US20160024233A1 (en) | 2016-01-28 |
| HK1220607A1 (zh) | 2017-05-12 |
| JP2022037143A (ja) | 2022-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12016500094A1 (en) | Autotaxin inhibitors | |
| TN2015000278A1 (en) | Autotaxin inhibitors | |
| PH12015501291A1 (en) | Functionalized exendin-4 derivatives | |
| MX2014011818A (es) | Anticuerpos biespecificos contra inductor debil de la apoptosis relacionado con el tnf (tweak) humana e il17 humana y usos de los mismos. | |
| IL236123A0 (en) | Preparations containing n-[4,2-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-4,1-dihydro-4-oxoquinoline-3-carboxamide for use in the treatment of cftr-mediated disorders | |
| MX356728B (es) | Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2. | |
| MX2015015518A (es) | Metodos y composiciones para el tratamiento del cancer. | |
| MX2015009058A (es) | Composiciones y metodos para tratar la inflamacion cronica y las enfermedades inflamatorias. | |
| IN2015DN03327A (enExample) | ||
| PH12014501991B1 (en) | Phenicol antibacterials | |
| SMT201600151B (it) | Nuovi composti bisostituiti di 3, 4-diammino-3-ciclobuten-1, 2-dione utili nel trattamento di patologie mediate da chemiochine | |
| MX349224B (es) | Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa. | |
| WO2014044794A3 (en) | Pharmaceutical composition | |
| MX2017007054A (es) | Composiciones y métodos para usar solabegron de liberación modificada para sintomas del tracto urinario inferior. | |
| MX2013013649A (es) | Compuestos de quinona para tratar enfermedades mediadas por ape1. | |
| WO2015059463A3 (en) | Treatment of beta-catenin related diseases8 | |
| EP3223809A4 (en) | Amino acid compositions for the treatment of symptoms of disease | |
| LT2968428T (lt) | Antioksidantinį poveikį turinti flavonoidų pagrindu paremta kompozicija farmaciniam, mitybiniam arba kosmetiniam panaudojimui | |
| IN2014DN07326A (enExample) | ||
| WO2017079403A3 (en) | Polymeric nanoparticles | |
| WO2014147503A3 (en) | Anti-bag3 antibodies for therapeutic use | |
| BR112015016033A2 (pt) | composições e métodos para tratamento de infecções por bactérias | |
| PH12015502019A1 (en) | Sequestrants of advanced glycation end product (age) precursors | |
| MX2014004742A (es) | Nuevos agentes antibacterianos de fenicol. | |
| CN301991818S (zh) | 家具连接件（易系列） |